TY - JOUR
T1 - Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia
T2 - a molecular classification with implications for targeted therapies
AU - Agathangelidis, Andreas
AU - Darzentas, Nikos
AU - Hadzidimitriou, Anastasia
AU - Brochet, Xavier
AU - Murray, Fiona
AU - Yan, Xiao-Jie
AU - Davis, Zadie
AU - van Gastel-Mol, Ellen J
AU - Tresoldi, Cristina
AU - Chu, Charles C
AU - Cahill, Nicola
AU - Giudicelli, Veronique
AU - Tichy, Boris
AU - Pedersen, Lone Bredo
AU - Foroni, Letizia
AU - Bonello, Lisa
AU - Janus, Agnieszka
AU - Smedby, Karin
AU - Anagnostopoulos, Achilles
AU - Merle-Beral, Helene
AU - Laoutaris, Nikolaos
AU - Juliusson, Gunnar
AU - di Celle, Paola Francia
AU - Pospisilova, Sarka
AU - Jurlander, Jesper
AU - Geisler, Christian
AU - Tsaftaris, Athanasios
AU - Lefranc, Marie-Paule
AU - Langerak, Anton W
AU - Oscier, David Graham
AU - Chiorazzi, Nicholas
AU - Belessi, Chrysoula
AU - Davi, Frederic
AU - Rosenquist, Richard
AU - Ghia, Paolo
AU - Stamatopoulos, Kostas
PY - 2012
Y1 - 2012
N2 - Mounting evidence indicates that grouping of chronic lymphocytic leukemia (CLL) into distinct subsets with stereotyped BCRs is functionally and prognostically relevant. However, several issues need revisiting, including the criteria for identification of BCR stereotypy and its actual frequency as well as the identification of "CLL-biased" features in BCR Ig stereotypes. To this end, we examined 7596 Ig VH (IGHV-IGHD-IGHJ) sequences from 7424 CLL patients, 3 times the size of the largest published series, with an updated version of our purpose-built clustering algorithm. We document that CLL may be subdivided into 2 distinct categories: one with stereotyped and the other with nonstereotyped BCRs, at an approximate ratio of 1:2, and provide evidence suggesting a different ontogeny for these 2 categories. We also show that subset-defining sequence patterns in CLL differ from those underlying BCR stereotypy in other B-cell malignancies. Notably, 19 major subsets contained from 20 to 213 sequences each, collectively accounting for 943 sequences or one-eighth of the cohort. Hence, this compartmentalized examination of VH sequences may pave the way toward a molecular classification of CLL with implications for targeted therapeutic interventions, applicable to a significant number of patients assigned to the same subset.
AB - Mounting evidence indicates that grouping of chronic lymphocytic leukemia (CLL) into distinct subsets with stereotyped BCRs is functionally and prognostically relevant. However, several issues need revisiting, including the criteria for identification of BCR stereotypy and its actual frequency as well as the identification of "CLL-biased" features in BCR Ig stereotypes. To this end, we examined 7596 Ig VH (IGHV-IGHD-IGHJ) sequences from 7424 CLL patients, 3 times the size of the largest published series, with an updated version of our purpose-built clustering algorithm. We document that CLL may be subdivided into 2 distinct categories: one with stereotyped and the other with nonstereotyped BCRs, at an approximate ratio of 1:2, and provide evidence suggesting a different ontogeny for these 2 categories. We also show that subset-defining sequence patterns in CLL differ from those underlying BCR stereotypy in other B-cell malignancies. Notably, 19 major subsets contained from 20 to 213 sequences each, collectively accounting for 943 sequences or one-eighth of the cohort. Hence, this compartmentalized examination of VH sequences may pave the way toward a molecular classification of CLL with implications for targeted therapeutic interventions, applicable to a significant number of patients assigned to the same subset.
KW - Amino Acid Sequence
KW - Gene Rearrangement, B-Lymphocyte
KW - Humans
KW - Immunoglobulin Heavy Chains
KW - Immunoglobulin Variable Region
KW - Immunophenotyping
KW - Leukemia, Lymphocytic, Chronic, B-Cell
KW - Models, Biological
KW - Molecular Diagnostic Techniques
KW - Molecular Sequence Data
KW - Molecular Targeted Therapy
KW - Receptors, Antigen, B-Cell
KW - Somatic Hypermutation, Immunoglobulin
U2 - 10.1182/blood-2011-11-393694
DO - 10.1182/blood-2011-11-393694
M3 - Journal article
C2 - 22415752
VL - 119
SP - 4467
EP - 4475
JO - Blood
JF - Blood
SN - 0006-4971
IS - 19
ER -